Todos os estudos
RecrutamentoNAINTERVENCIONISTA

Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease

The WILL MANAGE study aims to find better ways to prevent reoccurring bleeding in people who have Von Willebrand Disease (VWD). VWD is a genetic condition that affects how your blood clots, leading to more bleeding than usual. This study focuses on reducing serious stomach bleeding or severe nosebleeds through two different ways of managing the condition: a new, specially designed management plan and the care usually given. Researchers want to see if the new approach can lower the number of times these serious bleeds happen again. It's a randomised study, meaning participants will be assigned to one of the two groups by chance.

Em resumo

Status
Recrutamento
Fase
NA
Patrocinador
University Hospital, Lille
Meta de inscrição
66
Iniciar
10 de mar de 2026
Conclusão estimada
01 Mar 2032

Sobre o que é este estudo?

Von Willebrand Disease (VWD) is a common inherited bleeding disorder, meaning it's passed down through families. People with VWD don't have enough of a protein called von Willebrand factor, or it doesn't work properly. This protein plays a key role in helping your blood clot, so if it's faulty, you might experience more bleeding than usual. This could include things like heavy periods, easy bruising, or prolonged bleeding from cuts.

Sometimes, VWD can lead to more serious bleeding, such as bleeding in the stomach or gut (gastrointestinal bleeding) or very severe nosebleeds. These can be difficult to manage and can significantly impact a person's life. Doctors are always looking for ways to better prevent these serious bleeding episodes from happening again.

This study, called WILL MANAGE, is designed to compare two different ways of managing VWD in people who have had these serious bleeding problems. One approach is the 'standard of care,' which is the usual treatment doctors currently give. The other is a new, structured management plan developed by doctors and specialists. The goal is to see if this new approach can help reduce how often these serious stomach bleeds or nosebleeds happen again, ultimately improving the health and quality of life for people with VWD.

Pontos principais

  • This study aims to make serious bleeding less common in VWD.
  • It compares a new management plan to current standard care.
  • Focus is on stomach/gut bleeding and severe nosebleeds.
  • Participation involves being randomly assigned to one of two care groups.
  • You must have an inherited form of VWD and be aged 18+.
  • You can stop participating at any time if you wish.

Quem pode ser elegível?

To join this study, you need to be an adult aged 18 or over. You must have been diagnosed with Von Willebrand Disease that you were born with, not a form that developed later in life. A key part of joining is having experienced certain types of bleeding: either bleeding in your stomach or gut (which could be obvious, like vomiting blood, or less obvious, causing anaemia), or very severe nosebleeds that required blood transfusions or special treatments.

You also need to be part of a social security scheme, like the NHS, and be able to give your full permission to take part by signing a consent form.

However, there are reasons you might not be able to join. These include if your VWD developed later in life, if you have certain reactions to VWF treatments, some medical conditions like severe liver disease or cancer treatment, if you are pregnant or breastfeeding, or if you are unable to understand and give consent.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have Von Willebrand Disease that you were born with?
  3. Have you had serious stomach/gut bleeding or very severe nosebleeds?
  4. Are you able to give your informed consent to join the study?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

The study involves following one of two management plans for your Von Willebrand Disease. You'll be randomly assigned to either the new, special management plan or the standard care plan. This means you won't get to choose which plan you are on, and neither will your doctor in the study. You will have regular contact with the study team, who will monitor your health and any bleeding episodes you experience. This could involve clinic visits and assessments to track your progress. The total duration of your participation in the study will be explained by the study team, including how long you will be on your assigned management plan and any follow-up checks. Full details will be provided before you agree to take part.

Riscos e benefícios potenciais

Taking part in a study like this always has potential benefits and risks. A potential benefit is that you might receive careful, expert management of your VWD, and if the new management plan is more effective, you could experience fewer serious bleeding episodes. However, there's also the chance that the new approach might not work better than standard care. As with any medical care, there could be side effects or inconveniences from treatments or assessments, but the study team will monitor you closely. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (17)

  • CHU Lille
    Código postal verificado
    Lille, France· Ainda não recrutando
  • CHU Tours
    Código postal verificado
    Tours, France· Ainda não recrutando
  • CHU Amiens
    Código postal verificado
    Amiens, France· Ainda não recrutando
  • CHRU Brest
    Código postal verificado
    Brest, France· Ainda não recrutando
  • Hôpital cardiologique Louis Pradel
    Código postal verificado
    Bron, França· Ainda não recrutando
  • CHU Caen
    Código postal verificado
    Caen, França· Ainda não recrutando
  • CH Chambery
    Código postal verificado
    Chambéry, France· Ainda não recrutando
  • CHU Clermont-Ferrand
    Código postal verificado
    Clermont-Ferrand, França· Ainda não recrutando
  • CHU Dijon
    Código postal verificado
    Dijon, França· Ainda não recrutando
  • AP-HP Hôpital Kremlin Bicetre
    Código postal verificado
    Le Kremlin-Bicêtre, France· Ainda não recrutando
  • AP-HM Hôpital Timone
    Código postal verificado
    Marselha, França· Ainda não recrutando
  • CHU Montpellier
    Código postal verificado
    Montpellier, France· Recrutamento

Perguntas frequentes

What is Von Willebrand Disease?

It's a common inherited blood disorder where your blood doesn't clot as well as it should, leading to more bleeding.

What kind of bleeding is this study interested in?

It focuses on serious bleeding in the stomach or gut, or very severe nosebleeds that have happened again.

Will I get to choose my treatment in the study?

No, you'll be randomly assigned to either the new management plan or the standard care plan, like drawing lots.

Quanto tempo estarei no estudo?

The study team will tell you the exact duration, including treatments and follow-up, before you make a decision.

Posso sair do estudo se mudar de ideia?

Yes, you can leave the study at any time, and it won't affect the medical care you usually receive.

Como saber mais

Marie Caillierez

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Algorithm-based Management to Reduce the Recurrence of GI Bl…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.